106730-54-5

Oprinone is an injection developed by Japan Co., Ltd. for the treatment of acute heart failure. It is a specific PDEⅢ inhibitor that selectively blocks cAMP and has high selectivity for the inhibition of human cardiac PDEⅢ.

Olprinone is used in the treatment of acute myocardial insufficiency.

ChEBI: Olprinone is a member of bipyridines.

1. In the treatment of heart failure, the main adverse reactions of opprinone are manifested in the circulatory system, including premature ventricular contraction, tachycardia, increased ventricular tachyarrhythmia, and increased heart rate. Electric monitoring;
2. As a vasodilator, patients with renal insufficiency should use it in low doses. Long-term oral administration may lead to increased long-term mortality due to large adverse reactions, so it is only used for a short period of time.

4-(Dimethylamino)-3-(pyrimido[1,2-α]pyridin-6-yl)-3-buten-2-one and cyanoacetamide in dimethylformamide at 80~ Heating at 90°C for 12h to obtain Operinone.

Store at -20°C

[1] Patent: CN106349246, 2017, A. Location in patent: Paragraph 0023; 0028; 0029